Buckingham Capital Management Inc. Trims Position in Eli Lilly and Company (NYSE:LLY)

Buckingham Capital Management Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 17.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,216 shares of the company’s stock after selling 1,784 shares during the period. Buckingham Capital Management Inc.’s holdings in Eli Lilly and Company were worth $7,279,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the period. Quent Capital LLC grew its stake in shares of Eli Lilly and Company by 5.3% during the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after buying an additional 249 shares during the last quarter. Baron Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 9.3% in the first quarter. Baron Wealth Management LLC now owns 445 shares of the company’s stock worth $346,000 after buying an additional 38 shares during the period. Winthrop Capital Management LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at $13,678,000. Finally, Bleakley Financial Group LLC increased its stake in Eli Lilly and Company by 4.4% in the first quarter. Bleakley Financial Group LLC now owns 48,205 shares of the company’s stock worth $37,502,000 after purchasing an additional 2,041 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.2 %

Eli Lilly and Company stock opened at $833.08 on Monday. The business’s 50-day simple moving average is $896.31 and its two-hundred day simple moving average is $869.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $790.86 billion, a PE ratio of 89.90, a PEG ratio of 3.15 and a beta of 0.43. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the company posted $0.10 EPS. Eli Lilly and Company’s quarterly revenue was up 20.4% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.62%. Eli Lilly and Company’s payout ratio is 56.22%.

Analyst Ratings Changes

Several research analysts recently commented on LLY shares. Citigroup raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Finally, BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,008.41.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.